Aurora Cannabis (NASDAQ:ACB) Announces Earnings Results, Beats Expectations By $0.17 EPS

Posted by Francis Steltz on Aug 7th, 2026

Aurora Cannabis (NASDAQ:ACB – Get Free Report) announced its earnings results on Wednesday. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.17, Zacks reports. Aurora Cannabis had a positive return on equity of 4.33% and a negative net margin of 32.26%.The company had revenue of $47.62 million for the quarter, compared to analysts’ expectations of $47.45 million.

Here are the key takeaways from Aurora Cannabis’ conference call:

International medical cannabis revenue rose 17% to CAD 43 million, with international markets contributing 64% of total revenue, driven particularly by Germany. Aurora also reported strong performance in Poland, Australia, and New Zealand.
Consolidated adjusted gross margin was 58%, at the high end of fiscal 2027 guidance, supported by international sales and manufacturing efficiencies. Aurora highlighted genetics and operational improvements that can increase yields by up to 40% while improving potency and quality.
Quarterly revenue was CAD 67.6 million and adjusted EBITDA fell to CAD 3.4 million from CAD 10.8 million year over year, primarily due to lower Canadian medical reimbursement rates and the planned exit from lower-margin Canadian consumer cannabis.
Aurora ended the quarter with nearly CAD 150 million in cash and no debt, providing flexibility for international investment and acquisitions. The Safari Flower acquisition was adjusted-EBITDA accretive in Q1 and adds EU GMP-certified production capacity.
Management expects fiscal Q2 revenue and adjusted EBITDA to increase sequentially, with growth led by Germany, Poland, Australia, and New Zealand, while reaffirming its fiscal 2027 outlook despite Canadian reimbursement headwinds.

Aurora Cannabis Stock Performance

Shares of Aurora Cannabis stock opened at $2.98 on Friday. The firm has a fifty day moving average of $2.91 and a two-hundred day moving average of $3.35. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.32 and a current ratio of 5.94. The stock has a market capitalization of $184.58 million, a price-to-earnings ratio of -2.11 and a beta of 0.58. Aurora Cannabis has a 52 week low of $2.56 and a 52 week high of $6.66.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ACB. Wall Street Zen upgraded shares of Aurora Cannabis from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings raised shares of Aurora Cannabis from a “sell (d-)” rating to a “sell (d)” rating in a research note on Tuesday, June 16th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Read Our Latest Report on ACB

Hedge Funds Weigh In On Aurora Cannabis

Institutional investors have recently modified their holdings of the stock. Mackenzie Financial Corp grew its holdings in Aurora Cannabis by 64.3% during the fourth quarter. Mackenzie Financial Corp now owns 55,709 shares of the company’s stock valued at $237,000 after purchasing an additional 21,800 shares during the period. Barclays PLC raised its stake in Aurora Cannabis by 93.5% during the 4th quarter. Barclays PLC now owns 33,709 shares of the company’s stock worth $142,000 after buying an additional 16,292 shares during the period. Brooklyn Investment Group acquired a new stake in Aurora Cannabis during the 4th quarter worth $197,000. State of Wyoming bought a new stake in shares of Aurora Cannabis in the fourth quarter worth about $168,000. Finally, Jones Financial Companies Lllp raised its position in shares of Aurora Cannabis by 9,615.6% during the first quarter. Jones Financial Companies Lllp now owns 52,270 shares of the company’s stock worth $229,000 after purchasing an additional 51,732 shares during the period. 47.63% of the stock is currently owned by institutional investors and hedge funds.

About Aurora Cannabis

(Get Free Report)

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.